View Item 

Show simple item record

Comparison of Safety and Efficacy of Insulin Glargine and Neutral Protamine Hagedorn Insulin in Older Adults with Type 2 Diabetes Mellitus: Results from a Pooled Analysis

dc.contributor.authorLee, Pearl G.en_US
dc.contributor.authorChang, Annetteen_US
dc.contributor.authorBlaum, Caroline S.en_US
dc.contributor.authorVlajnic, Aleksandraen_US
dc.contributor.authorGao, Lingen_US
dc.contributor.authorHalter, Jeffrey B.en_US
dc.date.accessioned2012-03-16T15:55:30Z
dc.date.available2013-03-04T15:29:55Zen_US
dc.date.issued2012-01en_US
dc.identifier.citationLee, Pearl; Chang, Annette; Blaum, Caroline; Vlajnic, Aleksandra; Gao, Ling; Halter, Jeffrey (2012). "Comparison of Safety and Efficacy of Insulin Glargine and Neutral Protamine Hagedorn Insulin in Older Adults with Type 2 Diabetes Mellitus: Results from a Pooled Analysis." Journal of the American Geriatrics Society (1): 51-59. <http://hdl.handle.net/2027.42/90150>en_US
dc.identifier.issn0002-8614en_US
dc.identifier.issn1532-5415en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/90150
dc.publisherMedical Information Pressen_US
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherDiabetes Mellitusen_US
dc.subject.otherInsulinen_US
dc.subject.otherGeriatricen_US
dc.titleComparison of Safety and Efficacy of Insulin Glargine and Neutral Protamine Hagedorn Insulin in Older Adults with Type 2 Diabetes Mellitus: Results from a Pooled Analysisen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelGeriatricsen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.identifier.pmid22239291en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/90150/1/jgs3773.pdf
dc.identifier.doi10.1111/j.1532-5415.2011.03773.xen_US
dc.identifier.sourceJournal of the American Geriatrics Societyen_US
dc.identifier.citedreferenceAbraira C, Colwell JA, Nuttall FQ et al. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM): Results of the feasibility trial. Diabetes Care 1995; 18: 1113 – 1123.en_US
dc.identifier.citedreferenceBretzel RG, Nuber U, Landgraf W et al. Once‐daily basal insulin glargine versus thrice‐daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): An open randomised controlled trial. Lancet 2008; 371: 1073 – 1084.en_US
dc.identifier.citedreferenceJanka HU, Plewe G, Riddle MC et al. Comparison of basal insulin added to oral agents versus twice‐daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005; 28: 254 – 259.en_US
dc.identifier.citedreferenceFariello RG. Pharmacodynamic and pharmacokinetic features of cabergoline. Rationale for use in Parkinson's disease. Drugs 1998; 55 ( Suppl 1 ): 10 – 16.en_US
dc.identifier.citedreferencePan CY, Sinnassamy P, Chung KD et al. Insulin glargine versus NPH insulin therapy in Asian type 2 diabetes patients. Diabetes Res Clin Pract 2007; 76: 111 – 118.en_US
dc.identifier.citedreferenceEliaschewitz FG, Calvo C, Valbuena H et al. Therapy in type 2 diabetes: Insulin glargine versus NPH insulin both in combination with glimepiride. Arch Med Res 2006; 37: 495 – 501.en_US
dc.identifier.citedreferenceKawamori R. Efficacy and safety of insulin glargine in concurrent use with oral hypoglycaemic agents for the treatment of type 2 diabetes patients. Rinsho Iyaku 2003; 19: 445 – 464.en_US
dc.identifier.citedreferenceBazzano LA, Lee LJ, Shi L et al. Safety and efficacy of glargine compared with NPH insulin for the treatment of Type 2 diabetes: A meta‐analysis of randomized controlled trials. Diabet Med 2008; 25: 924 – 932.en_US
dc.identifier.citedreferenceRosenstock J, Dailey G, Massi‐Benedetti M et al. Reduced hypoglycemia risk with insulin glargine: A meta‐analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care 2005; 28: 950 – 955.en_US
dc.identifier.citedreferenceRosenstock J, Riddle MC. Insulin therapy in type 2 diabetes. In: Cefalu WT, Gerich JE, LeRoith D, ed. The CADRE Handbook of Diabetes Management. New York: Medical Information Press. 2004, pp 145 – 168.en_US
dc.identifier.citedreferenceChelliah A, Burge MR. Hypoglycaemia in elderly patients with diabetes mellitus: Causes and strategies for prevention. Drugs Aging 2004; 21: 511 – 530.en_US
dc.identifier.citedreferenceSiderowf A. Parkinson's disease: Clinical features, epidemiology and genetics. Neurol Clin 2001; 19: 565 – 578, vi.en_US
dc.identifier.citedreferenceJanka HU, Plewe G, Busch K. Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus. J Am Geriatr Soc 2007; 55: 182 – 188.en_US
dc.identifier.citedreferenceGrossman SP. The role of glucose, insulin and glucagon in the regulation of food intake and body weight. Neurosci Biobehav Rev 1986; 10: 295 – 315.en_US
dc.identifier.citedreferenceZammitt NN, Frier BM. Hypoglycemia in type 2 diabetes: Pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care 2005; 28: 2948 – 2961.en_US
dc.identifier.citedreferenceBlettner M, Sauerbrei W, Schlehofer B et al. Traditional reviews, meta‐analyses and pooled analyses in epidemiology. Int J Epidemiol 1999; 28: 1 – 9.en_US
dc.identifier.citedreferenceMooradian AD, Bernbaum M, Albert SG. Narrative review: A rational approach to starting insulin therapy. Ann Intern Med 2006; 145: 125 – 134.en_US
dc.identifier.citedreferenceAnderson G, Horvath J. The growing burden of chronic disease in America. Public Health Rep 2004; 119: 263 – 270.en_US
dc.identifier.citedreferenceLee PG, Cigolle C, Blaum C. The co‐occurrence of chronic diseases and geriatric syndromes: The Health and Retirement Study. J Am Geriatr Soc 2009; 57: 511 – 516.en_US
dc.identifier.citedreferenceMatyka K, Evans M, Lomas J et al. Altered hierarchy of protective responses against severe hypoglycemia in normal aging in healthy men. Diabetes Care 1997; 20: 135 – 141.en_US
dc.identifier.citedreferenceDharmarajan TS, Russell RO, Dabhi K. Recurrent, refractory hypoglycemia presenting as a behavioral disorder in an older woman. J Am Geriatr Soc 1999; 47: 380 – 381.en_US
dc.identifier.citedreferenceKumari J, Dharmarajan TS. Insulin glargine induced persistent intractable hypoglycemia, with variable presentations in older diabetic patients: An experience of 4 cases. J Am Med Dir Assoc 2009; 10: 672 – 673.en_US
dc.identifier.citedreferenceNational Diabetes Fact Sheet, 2007. Centers for Disease Control and Prevention [on‐line]. Available at http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2007.pdf Accessed December 10, 2010.en_US
dc.identifier.citedreferenceBoyle JP, Honeycutt AA, Narayan KM et al. Projection of diabetes burden through 2050: Impact of changing demography and disease prevalence in the U.S. Diabetes Care 2001; 24: 1936 – 1940.en_US
dc.identifier.citedreferenceBrown AF, Mangione CM, Saliba D et al. Guidelines for improving the care of the older person with diabetes mellitus. J Am Geriatr Soc 2003; 51 ( Suppl 5 ): S265 – S280.en_US
dc.identifier.citedreferenceAmerican Diabetes Association. Standards of Medical Care in Diabetes—2010. Diabetes Care 2010; 33 ( Suppl 1 ): S11 – S61.en_US
dc.identifier.citedreferenceUK Prospective Diabetes Study Group, UKPDS. U.K. Prospective Diabetes Study 16. Overview of 6 years’ therapy of type II diabetes: A progressive disease. Diabetes 1995; 44: 1249 – 1258.en_US
dc.identifier.citedreferenceUK Prospective Diabetes Study (UKPDS) Group. Intensive blood‐glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837 – 853.en_US
dc.identifier.citedreferenceWright A, Burden ACF, Paisey RB et al.; for the U.K. Prospective Diabetes Study Group. Sulfonylurea inadequacy: Efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002; 25: 330 – 336.en_US
dc.identifier.citedreferencePerez N, Moisan J, Sirois C et al. Initiation of insulin therapy in elderly patients taking oral antidiabetes drugs. Can Med Assoc J 2009; 180: 1310 – 1316.en_US
dc.identifier.citedreferenceDonnan PT, Steinke DT, Newton RW et al. Changes in treatment after the start of oral hypoglycaemic therapy in type 2 diabetes: A population‐based study. Diabet Med 2002; 19: 606 – 610.en_US
dc.identifier.citedreferenceKorytkowski M. When oral agents fail: Practical barriers to starting insulin. Int J Obes Relat Metab Disord 2002; 26 ( Suppl 3 ): S18 – S24.en_US
dc.identifier.citedreferenceHunt LM, Valenzuela MA, Pugh JA. NIDDM patients’ fears and hopes about insulin therapy: The basis of patient reluctance. Diabetes Care 1997; 20: 292 – 298.en_US
dc.identifier.citedreferenceBrunton S, Carmichael B, Funnell M et al. Type 2 diabetes: The role of insulin. J Fam Pract 2005; 54: 445 – 452.en_US
dc.identifier.citedreferencePapa G, Fedele V, Chiavetta A et al. Therapeutic options for elderly diabetic subjects: Open label, randomized clinical trial of insulin glargine added to oral antidiabetic drugs versus increased dosage of oral antidiabetic drugs. Acta Diabetol 2008; 45: 53 – 59.en_US
dc.identifier.citedreferenceHeinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T. Time‐action profile of the long‐acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000; 23 ( 5 ): 644 – 649.en_US
dc.identifier.citedreferenceRiddle MC, Rosenstock J, Gerich J. Insulin Glargine 4002 Study Investigators. The Treat‐to‐Target Trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080 – 3086.en_US
dc.identifier.citedreferenceMassi Benedetti M, Humburg E, Dressler A et al. A one‐year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Horm Metab Res 2003; 35: 189 – 196.en_US
dc.identifier.citedreferenceFritsche A, Schweitzer MA, Häring H‐U. Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes: A randomized, controlled trial. Ann Intern Med 2003; 138: 952 – 959.en_US
dc.identifier.citedreferenceYki‐Jarvinen H, Kauppinen‐Makelin R, Tiikkainen M et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: The LANMET study. Diabetologia 2006; 49: 442 – 451.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
jgs3773.pdf
Size:
131.8KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.